Terms: = Gastric cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
5 results:
1. NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating Akt pathway.
Kang W; Zhang J; Huang T; Zhou Y; Wong CC; Chan RCK; Dong Y; Wu F; Zhang B; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF
Oncogene; 2021 Mar; 40(9):1578-1594. PubMed ID: 33452458
[TBL] [Abstract] [Full Text] [Related]
2. MUC16 mutation predicts a favorable clinical outcome and correlates decreased Warburg effect in gastric cancer.
Zhao H; Zhang L
Biochem Biophys Res Commun; 2018 Dec; 506(4):780-786. PubMed ID: 30389134
[TBL] [Abstract] [Full Text] [Related]
3. Genetic variants in the PI3K/PTEN/AKT/mtor pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic role of p-mtor expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer.
An JY; Kim KM; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
Int J Cancer; 2010 Jun; 126(12):2904-13. PubMed ID: 19739122
[TBL] [Abstract] [Full Text] [Related]
5. gastric cancer in the era of molecularly targeted agents: current drug development strategies.
Arkenau HT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):855-66. PubMed ID: 19363621
[TBL] [Abstract] [Full Text] [Related]
